“In Vitro Diagnostics Quality Control Market is expected to reach $1.61 Billion By 2029”, says Visiongain

08 January 2020
Pharma

Visiongain’s new report the In Vitro Diagnostics Quality Control Market Report : Forecasts by Type (Quality Control, Quality Assurance Services, Data Management Solutions), by Application (Immunochemistry, Hematology, Clinical chemistry, Molecular Diagnostics, Coagulation, Others), by End User (Hospitals, Home Care, Others), plus analysis of leading companies operating in the global In Vitro Diagnostics Quality Control market.

The rising number of accredited clinical laboratories, increasing third-party quality control services, and the strong presence of favorable regulatory bodies to drive global In Vitro Diagnostics Quality Control market over the projected period. In 2019, the global In Vitro Diagnostics Quality Control market was valued at $1.05 billion and is expected to reach $1.61 billion by 2029 at a CAGR of 4.4%. However, the unfavorable scenario of reimbursement in the IVD industry followed by the high cost of IVD quality control services is expected to hinder market growth over the coming years.

Increasing penetration of diagnostic laboratories by virtue of rising prevalence of chronic diseases such as cancer, cardiovascular diseases, diabetes, and infectious diseases. Rising prevalence of chronic diseases in developed as well as developing economies to encourage global In Vitro Diagnostics Quality Control industry over the coming years.

Strong regulatory bodies associated with the regular quality check of IVD instruments and monitoring of quality control are expected to strengthen the industry. Some prominent bodies are U.S. The Food and Drug Administration, Central Drug Standard Control Organization (CDSCO), Ministry of Health, Labor & Welfare (MHLW), Ministry of Health for South Africa, Medicines and Healthcare Products Regulatory Agency (MHRA), Health Canada, Therapeutic Goods Administration (TGA), and European Medicines Agency.

List of prominent players operating in global In Vitro Diagnostics Quality Control industry are Siemens Healthcare, Abbott Diagnostics, Inc, Bio-Rad Laboratories, Inc., Danaher Corporation, Roche Diagnostics, Sysmex Corporation, Sero AS, Thermo Fisher Scientific, Inc, Sun Diagnostics, LLC, Ortho Clinical Diagnostics, Inc., Randox Laboratories Ltd, Helena Laboratories Corporation, SeraCare Life Sciences, Inc, and Technopath Clinical Diagnostics.

Notes for Editors
If you are interested in a more detailed overview of this report, please send an e-mail to sara.peerun@visiongain.com or call her on +44 (0) 207 336 6100.

About Visiongain
Visiongain is one of the fastest growing and most innovative independent media companies in Europe. Based in London, UK, Visiongain produces a host of business-to-business reports focusing on the automotive, aviation, chemicals, cyber, defence, energy, food & drink, materials, packaging, pharmaceutical and utilities sectors.

Visiongain publishes reports produced by analysts who are qualified experts in their field. Visiongain has firmly established itself as the first port of call for the business professional who needs independent, high-quality, original material to rely and depend on.

Recent News

Visiongain Publishes Respiratory Inhalers Market Report 2021-2031

Product approval is a major milestone facing all key competitors in the respiratory inhalers market. Several strategies were implemented by key market players between 2015 and Jan 2021.

26 February 2021

Read

Visiongain Publishes Bile Duct Cancer Drugs Market Report to 2031

The global bile duct cancer drug market has been growing considerably owing to the rising incidence and prevalence rate of bile duct cancer patients worldwide, technological advancement in drug development, and healthcare spending.

22 February 2021

Read

Visiongain Publishes Big Data Analytics in Healthcare Market Report to 2031

The global Big Data Analytics in Healthcare market has been growing considerably owing to the rising technological advancement, growing investment, and cohesive government policies.

22 February 2021

Read

Visiongain Publishes Behavioural Health Market Report to 2031

The global behavioural Health market has been growing considerably owing to the rising pressure/stress at work, growing incidence and prevalence rate of depression and PTSD (Post Traumatic Stress Disorder) around the globe.

22 February 2021

Read

Kelloggs
3m
Thales
Shell
TEVA
Lockheed-Martin
Pfizer
Raytheon
Halliburton
Du-Pont
Honeywell
Daimler
BASF
Bayer
BP
BAE-Systems
Unilever